Grand Pharmaceutical Group Limited (0512.HK)
HKD 5.6
(-3.45%)
HKD 5.6
(-3.45%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 990.02 Million HKD | -14.82% |
| 2022 | 1.16 Billion HKD | -23.03% |
| 2021 | 1.51 Billion HKD | 89.1% |
| 2020 | 798.56 Million HKD | -24.85% |
| 2019 | 1.06 Billion HKD | 253.0% |
| 2018 | 301.04 Million HKD | -56.47% |
| 2017 | 691.64 Million HKD | -38.51% |
| 2016 | 1.12 Billion HKD | 7.75% |
| 2015 | 1.04 Billion HKD | 51.82% |
| 2014 | 687.52 Million HKD | 64.81% |
| 2013 | 417.16 Million HKD | 260.94% |
| 2012 | 115.57 Million HKD | 213.78% |
| 2011 | 36.83 Million HKD | -7.92% |
| 2010 | 40 Million HKD | 76.0% |
| 2009 | 22.72 Million HKD | -65.81% |
| 2008 | 66.47 Million HKD | 0.0% |
| 2007 | - HKD | 0.0% |
| 2006 | - HKD | 0.0% |
| 2005 | - HKD | 0.0% |
| 2004 | - HKD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.02 Billion HKD | 0.0% |
| 2023 Q4 | 990.02 Million HKD | 0.0% |
| 2023 Q2 | 881.27 Million HKD | 0.0% |
| 2023 FY | 990.02 Million HKD | -14.82% |
| 2022 Q4 | 1.16 Billion HKD | 0.0% |
| 2022 Q2 | 1.6 Billion HKD | 0.0% |
| 2022 FY | 1.16 Billion HKD | -23.03% |
| 2021 Q2 | 1.75 Billion HKD | 0.0% |
| 2021 FY | 1.51 Billion HKD | 89.1% |
| 2021 Q4 | 1.51 Billion HKD | 0.0% |
| 2020 Q4 | 798.56 Million HKD | 0.0% |
| 2020 Q2 | 1.04 Billion HKD | 0.0% |
| 2020 FY | 798.56 Million HKD | -24.85% |
| 2019 FY | 1.06 Billion HKD | 253.0% |
| 2019 Q4 | 1.06 Billion HKD | 0.0% |
| 2019 Q2 | 588.2 Million HKD | 0.0% |
| 2018 Q2 | 802.01 Million HKD | 0.0% |
| 2018 Q4 | 301.04 Million HKD | 0.0% |
| 2018 FY | 301.04 Million HKD | -56.47% |
| 2017 Q4 | 691.64 Million HKD | 0.0% |
| 2017 FY | 691.64 Million HKD | -38.51% |
| 2017 Q2 | 741.45 Million HKD | 0.0% |
| 2016 Q4 | 1.12 Billion HKD | 0.0% |
| 2016 Q2 | 846.54 Million HKD | 0.0% |
| 2016 FY | 1.12 Billion HKD | 7.75% |
| 2015 Q4 | 1.04 Billion HKD | 0.0% |
| 2015 FY | 1.04 Billion HKD | 51.82% |
| 2015 Q2 | 509.95 Million HKD | 0.0% |
| 2014 Q4 | 687.52 Million HKD | 0.0% |
| 2014 FY | 687.52 Million HKD | 64.81% |
| 2014 Q2 | 205.66 Million HKD | 0.0% |
| 2013 Q4 | 403.68 Million HKD | 0.0% |
| 2013 Q2 | 113.13 Million HKD | 0.0% |
| 2013 FY | 417.16 Million HKD | 260.94% |
| 2012 FY | 115.57 Million HKD | 213.78% |
| 2012 Q2 | 164.77 Million HKD | 0.0% |
| 2012 Q4 | 115.57 Million HKD | 0.0% |
| 2011 Q4 | 36.83 Million HKD | 0.0% |
| 2011 Q2 | 60.94 Million HKD | 0.0% |
| 2011 FY | 36.83 Million HKD | -7.92% |
| 2010 Q2 | 62.06 Million HKD | 0.0% |
| 2010 FY | 40 Million HKD | 76.0% |
| 2010 Q4 | 40 Million HKD | 0.0% |
| 2009 Q4 | 22.72 Million HKD | 0.0% |
| 2009 FY | 22.72 Million HKD | -65.81% |
| 2009 Q2 | 68.69 Million HKD | 0.0% |
| 2008 Q4 | 66.47 Million HKD | 0.0% |
| 2008 FY | 66.47 Million HKD | 0.0% |
| 2007 FY | - HKD | 0.0% |
| 2006 FY | - HKD | 0.0% |
| 2005 FY | - HKD | 0.0% |
| 2004 FY | - HKD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -47658.248% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | -745.282% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | -258.446% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | -1301.591% |
| Essex Bio-Technology Limited | 36.05 Million HKD | -2645.751% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | -7633.99% |
| PuraPharm Corporation Limited | 81.09 Million HKD | -1120.855% |
| SSY Group Limited | 1.94 Billion HKD | 49.166% |
| JBM (Healthcare) Limited | 43.8 Million HKD | -2160.338% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | -67.178% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 94.042% |